Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 13/20 | 0.48 |
| ▸ | HTR2A | P28223 | 8/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 8/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5585784 | 0.86 | ADRB2 (0.60) | HTR2CHTR2AKCNH2ADRB2HTR2B | |
| SCHEMBL5585823 | 0.86 | ADRB2 (0.60) | HTR2CHTR2AKCNH2ADRB2HTR2B | |
| SCHEMBL5585780 | 0.86 | ADRB2 (0.60) | HTR2CHTR2AKCNH2ADRB2HTR2B | |
| SCHEMBL10034652 | 0.82 | HTR2C (0.49) | HTR2CHTR2AKCNH2HTR2BPIM1 | |
| SCHEMBL10034646 | 0.82 | HTR2C (0.49) | HTR2CHTR2AKCNH2HTR2BPIM1 | |
| SCHEMBL15217043 | 0.82 | HTR2C (0.47) | HTR2CHTR2AKCNH2HTR2BPIM1 | |
| SCHEMBL5585597 | 0.81 | HTR2C (0.46) | HTR2CHTR2AKCNH2ADRB2HTR2B | |
| SCHEMBL5585599 | 0.81 | HTR2C (0.46) | HTR2CHTR2AKCNH2ADRB2HTR2B | |
| SCHEMBL6204964 | 0.79 | ADRB2 (0.58) | HTR2CHTR2AKCNH2ADRB2HTR2B | |
| SCHEMBL5585663 | 0.77 | HTR2C (0.51) | HTR2CHTR2AKCNH2HTR2BPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130225553-A1 | PYRAZOLOQUINOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225553-A1 | PYRAZOLOQUINOLINE COMPOUND | PDE9A, PDE5A, PDE2A | HTR2C 4031/4885HTR2A 3728/4885KCNH2 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.